Twitter | Search | |
Search Refresh
Drexel Biomed Feb 27
Drexel MS student Victoria Nash discusses how her graduate co-op with in helped give her a unique understanding of how Biomed classes and research translate to the industry. Watch full interview:
Reply Retweet Like
MarketObserver Mar 3
: csimarket/stocks/financials_glance.php?code=ONCE In contrast to the third quarter Sales improved by 22.88 % from $11 millions and increased losses from $-1.26 per share.
Reply Retweet Like
Sanford Health Feb 26
ICYMI: The latest “Newt’s World” podcast talks about gene therapy research by Dr. Jean Bennett and Dr. Katherine High, Sanford Lorraine Cross Award winners.
Reply Retweet Like
Hemophilia EPC Aug 13
The Chapter appreciates being a part of the Spark Therapeutics Volunteer Fair. Always an honor to see the great Dr. Kathy High.
Reply Retweet Like
French Consulate L.A May 6
French-American Symposium on Inherited Retinal Dystrophies (IRD) in Los Angeles. Thank you to our sponsors for making this event possible 👏🏼
Reply Retweet Like
Biomedical Zone 18 Jan 18
Gene therapy treatment for a rare inherited form of blindness from is now the most expensive medicine in North America at $850K 💰
Reply Retweet Like
ESHK_EventDriven Apr 2
(ONCE US) - says that as a result of withdrawing and refiling their premerger notification for Spark, the offer expiry is extended from April 3rd until May 2nd. By yesterday ~30% of Spark shares had been tendered into ... 1/2
Reply Retweet Like
Meir Barak | Tradenet - Day Trading Academy Aug 7
My . had an overwhelmingly rough start, gapping down -29%; this, an effect of rising clinical safety concerns. Scott and I had shorted the stock under the long-held $52.50 support level, profiting an enjoyable $0.50 on the breakdown. 😎💰
Reply Retweet Like
Christina Fasser 14 Oct 17
FDA Advisory Committee Unanimously Recommends Approval Luxturna for rpe 65
Reply Retweet Like
Warren of Wall St 24 Mar 18
has had rather mediocre 5 years average EPS growth @ 0.1% per year
Reply Retweet Like
Michelle Dalton 20 Jul 17
receives pediatric disease designation for IRD; PDUFA expected Jan 2018
Reply Retweet Like
Roche Feb 25
Roche has entered into a definitive merger agreement to fully acquire Spark Therapeutics, a pioneering company in discovering, developing and delivering for a number of very specific inherited diseases.
Reply Retweet Like
MP Divakar 14 Oct 17
Reply Retweet Like
Week Facts 23 Feb 18
The approval for Spark Therapeutics offers an extraordinary intercession for a little gathering of patients with a vision-destroying...
Reply Retweet Like
LeadingBiotech 9 Dec 16
Congratulations to Kathy High and for winning the award for SPK-RPE65
Reply Retweet Like
Cal’s Cupcakes 🧁🧁🧁🧁🧁 19 Dec 17
Congratulations to our partners at on this historic achievement!
Reply Retweet Like
SEVA CRP, Inc. Aug 16
Spark Therapeutics shares slide as much as 28 percent after releasing results of hemophilia gene therapy trial
Reply Retweet Like
Warren of Wall St 12 Feb 18
25.1% expected growth🌱 next year is already accounted for in SP
Reply Retweet Like
Axovant Gene Therapies, Ltd 6 Jun 18
Axovant is pleased to announce in-licensing of investigational gene therapy AXO-Lenti-PD, for Parkinson’s disease. We are also excited to announce Fraser Wright, PhD, co-founder of , as our new Chief Technology Officer for gene therapies!
Reply Retweet Like
Johann Ödermann Oct 9
vs. in the lysosomal storage race. Spark to start trials of therapy for
Reply Retweet Like